Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs
28 Noviembre 2023 - 6:00AM
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology
company pioneering immuno-neurology, today announced management
will host two virtual events in December to discuss the Company’s
TREM2 and progranulin (PGRN) programs. The events will include
presentations from Alector’s management as well as leading
scientific and clinical experts who will provide their perspectives
on the biological and genetic rationale for the TREM2 and PGRN
targets, share an overview of the current treatment landscapes for
frontotemporal dementia and Alzheimer’s disease, and discuss the
significant unmet needs that remain in the treatment of these
neurodegenerative diseases.
Details of the webinars are as follows:
Diving Deep into TREM2: Uncovering its
Potential as a Therapeutic Target for Alzheimer’s
Disease
December 7, 2023, from 12:00 pm - 1:30 pm
Eastern Standard Time (EST)
Alector’s management team will be joined by:
- Michael Heneka, M.D., Director of the
Luxembourg Centre for Systems Biomedicine (LCSB) at the University
of Luxembourg and Adjunct Professor at the University of
Massachusetts Chan Medical School
- Reisa Sperling, M.D., Professor of Neurology
at Harvard Medical School and Director of the Center for Alzheimer
Research and Treatment at Brigham and Women’s Hospital and
Massachusetts General Hospital
A Detailed Review of PGRN: A Pivotal Stage Program for
Frontotemporal Dementia with Broad Additional Opportunities
Including Alzheimer’s Disease
December 13, 2023, from 11:00 am - 12:30 pm
EST
Alector’s management team will be joined by:
- Fenghua Hu, Ph.D., Associate Professor,
Department of Molecular Biology and Genetics and Weill Institute
for Cell and Molecular Biology at Cornell University
- Adam Boxer, M.D., Ph.D., Endowed Professor in
Memory and Aging in the Department of Neurology at the University
of California, San Francisco
A live question and answer session will follow
the formal presentations. To access the live webcasts of these
events, please register here for TREM2 and here for PGRN, or visit
“Events and Presentations” in the “Investors” section of the
Alector website at https://investors.alector.com. An archived
replay will be available for approximately 90 days following each
presentation.
About AlectorAlector is a
clinical-stage biotechnology company pioneering immuno-neurology, a
novel therapeutic approach for the treatment of neurodegenerative
diseases. Immuno-neurology targets immune dysfunction as a
root cause of multiple pathologies that are drivers of degenerative
brain disorders. Alector has discovered and is developing a broad
portfolio of innate immune system programs, designed to
functionally repair genetic mutations that cause dysfunction of the
brain’s immune system and enable rejuvenated immune cells to
counteract emerging brain pathologies. Alector’s immuno-neurology
product candidates are supported by biomarkers and seek to treat
indications, including Alzheimer’s disease and genetically defined
frontotemporal dementia patient populations. Alector is
headquartered in South San Francisco, California. For
additional information, please visit www.alector.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release include, but are
not limited to, statements regarding our business plans, business
strategy, product candidates, planned and ongoing preclinical
studies and clinical trials and the timing of data readouts from
such trials, expected milestones, expectations of our
collaborations, and financial and cash guidance. Such statements
are subject to numerous risks and uncertainties, including but not
limited to risks and uncertainties as set forth in Alector’s
Quarterly Report on Form 10-Q filed on November 7, 2023 with the
Securities and Exchange Commission (“SEC”), as well as the other
documents Alector files from time to time with the SEC. These
documents contain and identify important factors that could cause
the actual results for Alector to differ materially from those
contained in Alector’s forward-looking statements. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Alector specifically disclaims any
obligation to update any forward-looking statement, except as
required by law.
Alector Contacts:
AlectorKatie Hogan 202-549-0557katie.hogan@alector.com
1AB (media)Dan Budwick973-271-6085 dan@1abmedia.com
Argot Partners (investors)Laura Perry
212.600.1902alector@argotpartners.com
Alector (NASDAQ:ALEC)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Alector (NASDAQ:ALEC)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024